Shield Therapeutics To Work With Viatris To Bring Accrufer In The U.S.

(RTTNews) – Shield Therapeutics plc (STX.L) has entered into an exclusive, multi-year agreement with Viatris Inc. (VTRS) to co-commercialize Accrufer in the U.S. Shield will receive a $5 million one- time payment. Viatris will pay Shield a series of sales milestones up to a total

admin